Outcomes of patients with melioidosis treated with meropenem |
| |
Authors: | Cheng Allen C Fisher Dale A Anstey Nicholas M Stephens Dianne P Jacups Susan P Currie Bart J |
| |
Affiliation: | Menzies School of Health Research, Charles Darwin University, Casuarina NT 0811, Northern Territory, Darwin, Australia. |
| |
Abstract: | Melioidosis, an infection due to Burkholderia pseudomallei, is endemic in southeast Asia and northern Australia. We reviewed our experience with meropenem in the treatment of severe melioidosis in 63 patients over a 6-year period. Outcomes were similar to those of ceftazidime-treated patients (n = 153) despite a deliberate selection bias to more-unwell patients receiving meropenem. The mortality among meropenem-treated patients was 19%. One patient had a possible drug fever associated with the use of meropenem. We conclude that meropenem (1 g or 25 mg/kg every 8 h intravenously for >/=14 days) is an alternative to ceftazidime and imipenem in the treatment of melioidosis. The use of meropenem may be associated with improved outcomes in patients with severe sepsis associated with melioidosis. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|